FDA approves tucatinib in combination with chemotherapy for patients with HER2-positive metastatic breast cancer
The U.S. Food and Drug Administration (FDA) approved tucatinib in combination with chemotherapy (trastuzumab and capecitabine)…
Browsing: HER2-positive metastatic breast cancer